Complete Guide to Semaglutide: Everything You Need to Know

Semaglutide is a prescription GLP-1 receptor agonist medication. FDA-approved versions (Wegovy, Ozempic) demonstrated significant weight loss in clinical trials. Important: Compounded semaglutide is NOT FDA-approved. The FDA does not verify the safety or effectiveness of compounded medications. The studies summarized here do not establish the effectiveness of compounded semaglutide. Individual results vary significantly. This article is for educational purposes only and is not medical advice; talk with a licensed healthcare provider about whether any treatment is right for you.

This comprehensive guide covers everything you need to know about semaglutide for weight loss, from how it works to what the clinical data shows, costs, side effects, and whether it’s right for you.

What Is Semaglutide?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a type of medication that mimics the effects of a hormone your body naturally produces called GLP-1. This hormone plays a crucial role in regulating appetite, blood sugar levels, and how your body processes food.

The medication was initially developed and approved by the FDA for treating type 2 diabetes in 2017 under the brand name Ozempic. In 2021, a higher-dose version was approved specifically for chronic weight management under the brand name Wegovy (Source: FDA).

Brand Names and Forms

Semaglutide is available under several brand names:

• Ozempic: Includes separately labeled injection and tablet formulations for adults with type 2 diabetes; check the exact formulation and indication with your prescriber.
• Wegovy: Includes injection and tablet formulations. Approved uses and doses differ by formulation, age and indication; see the current label references below.
• Rybelsus: FDA-approved for type 2 diabetes, oral tablet form taken daily
• Compounded Semaglutide: Prepared individually for a patient by a state-licensed 503A compounding pharmacy based on a prescription. Compounded semaglutide is NOT FDA-approved.

Learn more about the differences between brand-name and compounded options in our guide to semaglutide costs without insurance.

How Semaglutide Works for Weight Loss

Wegovy labeling, sections 12.1–12.2, describes GLP-1 receptor activity, reduced calorie intake, glucose-dependent insulin/glucagon effects and delayed gastric emptying. These actions should not be treated as separately proven explanations for every patient’s weight change.

1. Appetite and Food Intake

A randomized crossover trial in 30 adults with obesity compared 12-week treatment periods using weekly semaglutide escalated to 1 mg or placebo. Participants reported less appetite and consumed less food with semaglutide. This does not promise freedom from hunger or the same response with every preparation.

2. Gastric Emptying

Semaglutide delays gastric emptying. The label also warns this may affect oral medication absorption; see the interaction section below. A pharmacologic effect does not establish a personal fullness or weight-loss timeline.

3. Blood Sugar Regulation

The label describes increased insulin secretion and reduced glucagon secretion in a glucose-dependent manner. This does not establish that smoother glucose levels explain an individual’s appetite response.

4. Energy Expenditure

In the 30-person trial above, resting metabolic rate adjusted for lean body mass did not differ between treatments. That result does not support promising a metabolic boost or establish the effect in every population or regimen.

FDA Approval and Medical Uses

Type 2 Diabetes

Semaglutide was first approved by the FDA in December 2017 as Ozempic for improving blood sugar control in adults with type 2 diabetes. The oral form, Rybelsus, was approved for diabetes in 2019.

Chronic Weight Management

In June 2021, the FDA approved Wegovy (semaglutide 2.4 mg) for chronic weight management in adults with:

• Body Mass Index (BMI) of 30 kg/m² or greater (obesity), OR
• BMI of 27 kg/m² or greater (overweight) with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol

Cardiovascular Benefits

In March 2024, the FDA expanded Wegovy’s approval to include reducing the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight conditions (Source: FDA).

Note on compounded semaglutide: The FDA approvals and indications described above apply to the FDA-approved brand-name products (Wegovy, Ozempic, Rybelsus). They do not apply to compounded semaglutide, which is not FDA-approved and has not been evaluated by the FDA for any use.

Forms of Semaglutide: Injectable vs Oral

Semaglutide is available in two main forms, each with distinct advantages and considerations.

Injectable Semaglutide

Administration: Once-weekly subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm

Doses available:

• Ozempic: 0.25 mg, 0.5 mg, 1 mg, 2 mg
• Wegovy injection: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg and 7.2 mg; these strengths are not all appropriate for every patient or indication
• Compounded: Strength prepared by the compounding pharmacy as directed by the prescriber

Effectiveness: Results from the cited branded-product trials should not be assumed to apply to compounded semaglutide. Individual results vary.

Oral Semaglutide

Administration: Daily tablet taken on an empty stomach, 30 minutes before eating or drinking

Labeled tablet strengths: Rybelsus: 3, 7 and 14 mg; Ozempic tablets: 1.5, 4 and 9 mg. Wegovy tablets: 1.5, 4, 9 and 25 mg. These include starting and escalation strengths, not just maintenance doses. Rybelsus and Ozempic tablets are not substitutable milligram-for-milligram; your clinician directs product selection and any switch.

Effectiveness: Compare the exact product, dose, indication and study population. A trial of one oral formulation does not establish that all tablets are less effective than all injections, or that a compounded preparation has the same outcomes.

Which Form Is Better?

The choice between injectable and oral semaglutide depends on your priorities:

Factor	Injectable	Oral
Clinical data	Depends on the specific product, dose and trial	Depends on the specific product, dose and trial
Convenience	Once weekly	Daily, strict timing requirements
Needle-free	No	Yes
Cost (brand-name)	$900-1,500/month	$900-1,000/month

The clinical figures above are from trials of FDA-approved products and do not apply to compounded semaglutide, whose effectiveness is not established by those studies. For a detailed comparison of the data, convenience, side effects, and costs, read our comprehensive guide to oral semaglutide vs injectable semaglutide.

Dosing and Administration

Important: Dosing is always directed by your prescribing clinician. The table below summarizes initial Wegovy injection escalation for reference; it is not a tablet schedule. It is not dosing instructions for compounded semaglutide. Do not adjust your own dose. Follow the specific plan your clinician gives you.

FDA-Approved Wegovy Titration Schedule (for reference)

Current Wegovy labeling, section 2.2, separates initial injection escalation from indication-specific maintenance. Escalation may be delayed for tolerability.

Timeframe	Dose	Purpose
Weeks 1-4	0.25 mg weekly	Initiation - body adjustment
Weeks 5-8	0.5 mg weekly	First dose increase
Weeks 9-12	1 mg weekly	Second dose increase
Weeks 13-16	1.7 mg weekly	Third dose increase
Week 17+	Determined by indication and tolerability	Maintenance; see below

For adult weight reduction, Wegovy injection maintenance is 1.7 or 2.4 mg weekly, with 2.4 mg recommended. The label permits an increase to 7.2 mg when additional loss is clinically indicated after tolerating 2.4 mg for at least four weeks. Other indications and pediatric dosing have separate instructions. These are label references, not instructions to increase your dose.

How to Inject Semaglutide

If your clinician prescribes an injectable, they and your pharmacy will give you instructions specific to your medication. General technique looks like this:

1. Choose your injection site: Abdomen (most common), front of thighs, or upper arm
2. Rotate injection sites: Use different locations each week to prevent skin irritation
3. Clean the area: Use an alcohol swab and let it dry completely
4. Inject: Follow the technique your clinician or pharmacy demonstrates for your specific product
5. Dispose properly: Place used needles in a sharps container

Oral Semaglutide Dosing

Rybelsus, Ozempic tablets and Wegovy tablets require product-specific escalation. Their labels direct taking tablets in the morning with the precautions below. Do not use the injection table for tablets or convert doses yourself:

• Take on an empty stomach: First thing in the morning before eating or drinking
• Use minimal water: Swallow whole with no more than 4 ounces of plain water
• Wait 30 minutes: Don’t eat, drink, or take other medications for at least 30 minutes
• Follow your clinician’s titration plan: Your prescriber determines your starting dose and any increases

How Effective Is Semaglutide?

Clinical Trial Results

STEP 1 randomized 1,961 adults with overweight or obesity, without diabetes, to weekly injected semaglutide with a target dose of 2.4 mg or placebo for 68 weeks. Both groups received lifestyle intervention.

Mean weight change at week 68: The published estimates were a 14.9% reduction with semaglutide and a 2.4% reduction with placebo. These are group results, not a forecast for an individual.

The primary report’s responder percentages below use participants with available week-68 data: 1,212 in the semaglutide group and 577 in the placebo group.

Weight-loss threshold	Semaglutide	Placebo
At least 5%	86.4%	31.5%
At least 10%	69.1%	12.0%
At least 15%	50.5%	4.9%
At least 20%	32.0%	1.7%

These percentages do not use all randomized participants as their denominators. The trial did not test compounded preparations; its results do not establish their effectiveness.

Real-World Data

A 2022 retrospective cohort from a weight-management referral center reported weight loss during semaglutide treatment. Its analysis included 175 patients at three months and 102 at six months. This was an observational records review, not a randomized comparison proving that routine care matches trial results. The smaller follow-up sample and selected setting matter when interpreting the findings; they do not promise an individual outcome or establish compounded-product effectiveness.

Factors Affecting Results

Individual results vary, and no specific outcome can be promised. Reported factors include:

• Starting weight: Higher starting weights often see greater absolute weight loss
• Product and dose: Results from STEP 1’s regimen do not establish the response to every formulation or dose
• Adherence: Consistent weekly dosing as directed by your clinician
• Lifestyle factors: Diet quality and physical activity
• Genetics: Some individuals respond differently to GLP-1 medications
• Medical conditions: Underlying metabolic issues can affect response

Weight Loss Timeline: What to Expect

STEP 1 followed participants for 68 weeks. Its group results do not establish a personal month-by-month weight-loss schedule, a guaranteed first-week appetite change or a date when weight loss will peak.

Review progress with your prescriber using your treatment goals, symptoms and the exact product prescribed. Dose escalation is a tolerability plan, not a schedule of promised weight milestones. Do not increase your dose to match someone else’s progress.

Discuss persistent symptoms or concerns about response with your care team. The study summary above describes the population and outcomes actually measured; it does not predict a fixed number of pounds to lose each month.

Side Effects and How to Manage Them

Side effects depend on the product, dose and patient. Severe or persistent symptoms need assessment; a trial percentage does not predict how long your symptoms will last.

Common Gastrointestinal Side Effects

Wegovy labeling, section 6.1, Table 3, reports these selected reactions across three adult weight-management trials of the 2.4 mg weekly injection. Treatment lasted up to 68 weeks, followed by seven weeks off treatment.

Reaction	Wegovy 2.4 mg injection (2,116 adults)	Placebo (1,261 adults)
Nausea	44%	16%
Diarrhea	30%	16%
Constipation	24%	11%
Vomiting	24%	6%
Abdominal pain and related abdominal symptoms	20%	10%

This pooled table is not STEP 1 alone. It does not describe every semaglutide dose, tablets or compounded preparations, and it does not establish a typical symptom duration.

Managing Mild Symptoms

These general self-care measures do not replace assessment of medication-related symptoms. Use the urgent-care instructions below for severe symptoms, and contact your clinician if you cannot keep food or fluids down.

For nausea: MedlinePlus guidance suggests smaller meals, bland foods and remaining upright after eating. Discuss persistent nausea and any medicines or supplements with your prescriber; this guidance is not a semaglutide-specific treatment trial.

For constipation: NIDDK guidance recommends adding fiber gradually and tailoring fluid intake to health, size and activity. Ask your clinician whether a fiber supplement or laxative is appropriate rather than choosing one solely from this article.

For diarrhea: NIDDK guidance emphasizes replacing fluids and electrolytes. People with diabetes, kidney disease or other health conditions should ask about suitable fluids and amounts. Many people can resume their usual diet when appetite returns; a restrictive diet is not automatically required.

Other Reported Effects

• Fatigue or decreased energy
• Headache
• Dizziness
• Increased heart rate; report a racing heartbeat at rest to your clinician
• Injection site reactions (redness, itching - injectable forms only)

Symptoms That Need Prompt Care

Wegovy’s Medication Guide gives these safety instructions:

• Severe abdominal pain that does not go away: Stop using Wegovy and contact your healthcare provider right away. Pain may extend to the back, with or without nausea or vomiting, and can signal pancreatitis.
• Face or throat swelling, trouble breathing or swallowing, or other signs of a serious allergic reaction: Stop using Wegovy and get medical help right away. Breathing difficulty or throat swelling requires emergency help.
• Upper abdominal pain, fever, yellowing skin or eyes, or clay-colored stools: Contact your provider for possible gallbladder problems.
• Changes in vision, a racing heartbeat at rest, or severe or persistent stomach problems: Tell your healthcare provider promptly.

This is not a complete symptom list or a diagnosis. Follow the instructions for your exact medication; do not wait for a routine visit when urgent symptoms occur.

For comprehensive strategies to manage side effects, including dietary recommendations, supplement suggestions, and when to contact your doctor, read our complete guide to managing semaglutide side effects.

Safety Considerations

Contraindications

Wegovy labeling, section 4, lists personal or family history of medullary thyroid carcinoma (MTC), MEN 2, and known hypersensitivity to semaglutide or its ingredients as contraindications. Your prescriber must assess the exact product and your history.

Pregnancy and Breastfeeding

For weight reduction or cardiovascular risk reduction, Wegovy labeling, sections 8.1–8.3, directs stopping when pregnancy is recognized and at least two months before a planned pregnancy. Its MASH indication has separate benefit-risk considerations. Contact your prescriber promptly about pregnancy or pregnancy plans so ongoing care can be arranged.

Breastfeeding is not recommended with Wegovy tablets. For Wegovy injection, the label calls for weighing breastfeeding benefits, the mother’s treatment need and potential infant risks. This does not establish that any preparation is safe during breastfeeding; discuss the exact product and infant-feeding plan with your clinician.

Use with Caution If You Have:

• History of pancreatitis: Discuss risks and benefits with your provider
• Diabetic retinopathy: May worsen initially in people with diabetes
• Kidney disease: Dehydration from GI side effects can worsen kidney function
• Gallbladder disease: Rapid weight loss can increase gallstone risk

Mental Health

In its January 2026 safety review, FDA found no increased risk of suicidal thoughts or behavior with GLP-1 medicines and requested removal of that warning from Wegovy and other affected labels. Still, report new or worsening depression, suicidal thoughts or unusual mood or behavior changes to your healthcare professional.

Drug Interactions

Semaglutide can interact with other medications:

• Insulin or insulin-releasing medicines such as sulfonylureas: Wegovy labeling warns of increased low-blood-sugar risk with these combinations. Your clinician may need to adjust those medicines; do not change doses yourself.
• Oral medications: Wegovy labeling, section 7.2, calls for monitoring their effects and considering closer clinical or laboratory monitoring when needed. It does not prescribe taking all oral medicines one hour before an injection. Oral semaglutide tablets have separate administration instructions.
• Medicines requiring laboratory monitoring, including warfarin: Ask your prescriber what monitoring is appropriate when treatment changes.

Always inform your healthcare provider about all medications, supplements, and herbal products you’re taking.

Long-Term Safety

Evidence extends beyond two years. SELECT randomized 17,604 adults aged 45 or older with established cardiovascular disease, BMI of at least 27 and no diabetes to weekly injected semaglutide 2.4 mg or placebo. Mean follow-up was 39.8 months; mean exposure to assigned treatment was 34.2 months. Those are different measures, not a claim that every participant took treatment for the entire follow-up.

The study reported fewer primary cardiovascular events with semaglutide, but adverse events leading to permanent treatment discontinuation occurred in 16.6% versus 8.2% with placebo. These findings inform benefit-risk assessment in the studied population; they do not prove lifelong safety, apply to every formulation or establish the safety of compounded preparations. Review ongoing benefits, adverse effects and treatment needs with your prescriber.

For detailed information about compounded semaglutide specifically, including how state-licensed compounding pharmacies operate, read our guide to compounded semaglutide safety.

Cost and Insurance Coverage

Brand-Name Costs

Without insurance, brand-name semaglutide is expensive:

• Wegovy: $349 per 28-day injection fill through Novo Nordisk’s self-pay offer ($399 for the 7.2 mg HD dose); Wegovy tablets are $149-$299 per 30-day fill. Prices checked October 3, 2026 on NovoCare; retail pharmacy list prices are higher, and the offer terms can change.
• Ozempic: $900-$1,000 per month (when used off-label for weight loss)
• Rybelsus: $900-$1,000 per month

Insurance Coverage

Insurance coverage varies significantly:

• For diabetes: Most insurance plans cover Ozempic for type 2 diabetes, though copays vary from $25-$500/month
• For weight loss: Coverage for Wegovy is limited. Many insurers exclude weight loss medications entirely or require extensive documentation and prior authorization
• Medicare: Does not currently cover weight loss medications, including Wegovy

Compounded Semaglutide

Compounded semaglutide, prepared by a state-licensed 503A compounding pharmacy, is often less expensive than brand-name products. For compounded options, keep these points in mind:

• Monthly cost: Generally lower than brand-name; pricing varies by provider
• FDA Status: Compounded semaglutide is NOT FDA-approved; the cited studies do not establish its effectiveness
• Prescription-based: Prepared individually for you based on your prescription
• Insurance: Typically not covered, but the out-of-pocket cost is often lower than brand-name

For our compounded semaglutide program, please see current pricing on our product page. Medical supervision is included.

Annual Cost Comparison (brand-name reference)

Option	Monthly Cost	Annual Cost
Wegovy injection (brand-name, self-pay offer)	$349 per 28-day fill ($399 for 7.2 mg HD)	$4,537 for 13 fills ($5,187 for 7.2 mg HD)
Ozempic (off-label)	$900-$1,000	$10,800-$12,000
Compounded semaglutide	See current pricing on our product page	Varies by provider

For a complete breakdown of pricing, hidden costs, discount programs, and strategies to save, read our comprehensive guide to semaglutide costs without insurance.

Who Should Use Semaglutide?

Weight-Management Eligibility

For adults, the weight-management criteria discussed here are:

• BMI ≥ 30 kg/m² (obesity), OR
• BMI ≥ 27 kg/m² (overweight) with at least one weight-related comorbidity such as:
  • High blood pressure (hypertension)
  • Type 2 diabetes
  • High cholesterol (dyslipidemia)
  • Obstructive sleep apnea
  • Cardiovascular disease

Current Wegovy labeling, section 1, covers adult weight management with injection or tablets alongside a reduced-calorie diet and increased activity. Injection also covers patients aged 12 and older with obesity; the tablet indication is for adults. Cardiovascular risk reduction and the injection’s MASH indication have separate criteria. These are not approvals for compounded preparations.

Who May Be a Candidate

Eligibility depends on the treatment indication and a clinical assessment, not a fixed number of pounds to lose. NIDDK guidance identifies health conditions, other medicines, family history, expected benefits and possible side effects as factors in choosing treatment.

Discuss your health goals, previous treatment experience, nutrition and activity needs, and barriers to ongoing care with your clinician. Follow-up should assess both benefits and tolerability. See the product-specific contraindications and pregnancy guidance above.

When Semaglutide May Not Be the Best Choice

Medication is not appropriate solely to change appearance. A clinician may recommend another approach if the product is contraindicated, risks outweigh expected benefits, or treatment does not suit your health needs. Difficulty making lifestyle changes is a reason to discuss additional support; this article cannot determine eligibility.

Alternatives to Semaglutide

Other GLP-1 Medications

Tirzepatide (Mounjaro, Zepbound):

• Type: Dual GLP-1 and GIP receptor agonist
• Clinical data: Trial data is for FDA-approved brands; the cited trials do not establish outcomes for compounded versions; individual results vary
• Dosing: Once-weekly injection, clinician-directed
• Cost: Brand-name typically $1,000-$1,600/month

For a detailed head-to-head comparison of the clinical data, side effects, cost, and which medication might be right for you, read our complete tirzepatide vs semaglutide comparison.

Liraglutide (Saxenda, Victoza):

• Type: Earlier GLP-1 medication
• Clinical data: In STEP 8, mean weight change at 68 weeks was −15.8% with weekly injected semaglutide 2.4 mg versus −6.4% with daily injected liraglutide 3.0 mg in adults with overweight or obesity without diabetes. This comparison concerns those trial regimens, not every formulation or individual outcome.
• Dosing: Daily injection; follow the instructions for the prescribed product
• Cost: $1,000-$1,400/month

Non-GLP-1 Weight Loss Medications

NIDDK’s medication overview describes these options:

• Phentermine-topiramate (Qsymia): An oral combination that may reduce hunger or increase fullness.
• Naltrexone-bupropion (Contrave): An oral combination that may reduce hunger or increase fullness.
• Orlistat (Xenical, Alli): An oral medicine that reduces absorption of dietary fat.

These medicines have different contraindications and interactions. Review the exact product with your prescriber; this list does not rank their effectiveness against semaglutide or provide a dosing plan.

Non-Medication Approaches

• Bariatric surgery: Can improve weight and obesity-related health problems. NIDDK’s surgery overview describes potential benefits; an individual surgical assessment is needed to weigh them against risks.
• Structured lifestyle programs: Look for nutrition and activity plans suited to your health, behavioral support and a maintenance plan. NIDDK’s program-selection guidance explains what to ask about evidence and ongoing support. A program’s weight-loss goal is not a guaranteed result.

How to Get Started with Semaglutide

Step 1: Consult a Healthcare Provider

You’ll need a prescription from a licensed healthcare provider. Options include:

• Your primary care physician: Can prescribe if experienced with weight management
• Obesity medicine specialist: Specialized expertise in weight loss medications
• Endocrinologist: Hormone specialists familiar with GLP-1 medications
• Telehealth services: Convenient online consultations with licensed providers

During your consultation, your provider will:

• Review your medical history and current medications
• Calculate your BMI and assess weight-related health conditions
• Discuss your weight loss goals and previous attempts
• Explain how semaglutide works, potential side effects, and what to expect
• Determine if you’re a good candidate
• Write a prescription if appropriate, and direct your dosing plan

Step 2: Choose Your Pharmacy Option

Brand-name from retail pharmacy:

• Standard pharmacies (CVS, Walgreens, etc.)
• Submit insurance for potential coverage
• Use manufacturer savings cards if eligible (up to $500-$650/month off)
• Most expensive option without insurance

Compounded from a state-licensed 503A compounding pharmacy:

• A state-licensed 503A compounding pharmacy prepares your medication individually, for you, based on your prescription
• Compounded semaglutide is NOT FDA-approved; the cited studies do not establish its effectiveness
• Note: a pharmacy may be “FDA-registered,” but FDA registration is not the same as FDA approval of the medication
• Typically includes medical oversight
• Our compounded semaglutide program includes provider consultations, medication, and ongoing support

Step 3: Start Treatment and Monitor Progress

Starting your prescribed product:

• Confirm your exact formulation, dose and administration instructions with your prescriber or pharmacist
• For injections, learn the technique for your specific device; tablets have different instructions
• Ask how to handle missed doses and when to contact the care team about symptoms

Ongoing monitoring:

Agree on a follow-up and weight-monitoring schedule with your clinician. The schedule should reflect your health, response and symptoms; urgent concerns should not wait for a routine visit.

Wegovy labeling calls for blood-glucose monitoring before and during treatment in patients with diabetes, kidney-function monitoring when adverse effects could cause dehydration, monitoring of existing diabetic retinopathy and regular heart-rate checks. Your clinician should determine which assessments and laboratory tests apply to you. Follow the instructions for the exact medication prescribed.

Lifestyle optimization:

• Discuss adequate nutrition and protein needs with your clinician or dietitian
• Agree on fluid intake suited to your health and any restrictions
• Choose physical activity and strength-building goals suited to your health and mobility
• Practice portion control and mindful eating
• Discuss whether tracking food or weight would help without worsening eating concerns

Step 4: Plan for Long-Term Maintenance

Weight loss with semaglutide typically occurs over many months. After reaching your goal weight:

• Follow your clinician’s plan: Whether to continue, adjust, or stop treatment is a decision to make with your clinician
• Possible dose adjustment: Your clinician may adjust your maintenance dose
• Strengthen habits: Use the weight loss period to establish sustainable healthy habits
• Regular monitoring: Continue follow-ups even after reaching goal weight

In trials of the FDA-approved product, weight regain after stopping was common. How long you stay on treatment is a decision for your clinician, not a fixed minimum.

Related reading: Curious why some people use lower, personalized doses? Read Microdosing Semaglutide: The Honest Guide to Low-Dose, Personalized GLP-1 Care.

Frequently Asked Questions

How fast does semaglutide work?

The STEP 1 results summarized above concern weight change over 68 weeks; they do not establish that most people notice appetite suppression in the first week or define a personal deadline for response. Discuss your progress and symptoms with your prescriber. See the timeline section.

Do I need to diet and exercise on semaglutide?

In trials of the FDA-approved products, semaglutide reduced appetite for many participants, and combining treatment with a healthy diet and regular exercise was part of the trial protocols. Results vary. Think of semaglutide as a tool that may make healthy choices easier, not a replacement for them.

What happens if I stop taking semaglutide?

In trials of the FDA-approved product, meaningful weight regain within a year of stopping was common. Individual experience varies. This doesn’t mean the medication “failed” - it means obesity is a chronic condition often requiring ongoing management, similar to medications for high blood pressure or cholesterol.

Can I drink alcohol on semaglutide?

Discuss alcohol use with your prescriber in the context of your health history and other medicines. Research on semaglutide for alcohol use disorder does not establish a safe drinking amount for someone taking it for weight management.

A 26-week randomized trial in 108 people with alcohol use disorder and obesity found fewer heavy-drinking days with injected semaglutide than placebo; both groups received cognitive behavioral therapy. A separate eight-week oral trial in 50 people with alcohol use disorder found fewer heavy-drinking days but no significant improvement in its primary laboratory craving outcome. These specific findings do not establish that everyone will crave less alcohol or have lower alcohol tolerance.

Is semaglutide safe?

Safety depends on the exact product and your health history. Wegovy labeling describes common gastrointestinal effects and serious risks, including pancreatitis, gallbladder problems and allergic reactions. It is contraindicated with a personal or family history of MTC, MEN 2 or known hypersensitivity to semaglutide or its ingredients. Compounded preparations do not undergo the same FDA premarket review. See the urgent-symptom section above and our safety guide; neither replaces an individual assessment.

How much does semaglutide cost?

Brand-name Wegovy injection is $349 per 28-day fill through Novo Nordisk’s self-pay offer ($399 for the 7.2 mg HD dose), checked October 3, 2026 on NovoCare; retail pharmacy list prices are higher. For compounded semaglutide pricing, please see current pricing on our product page. Insurance coverage for weight loss is limited, but coverage for diabetes (Ozempic) is more common. See our complete cost breakdown.

Is compounded semaglutide the same as Wegovy?

No. Compounded semaglutide is NOT FDA-approved; the cited trials do not establish its equivalence to approved products. The FDA does not verify the safety or effectiveness of compounded medications. It is prepared individually for a patient by a state-licensed 503A compounding pharmacy based on a prescription. It should not be assumed to be equivalent to, or to produce the same results as, FDA-approved Wegovy or Ozempic. For a detailed explanation of the regulatory status, see our guide on compounded semaglutide FDA approval. Individual results vary significantly.

What’s the difference between Ozempic and Wegovy?

The names cover different formulations and approved uses. Ozempic injection has a maximum recommended dose of 2 mg weekly; Ozempic tablets have a separate label. Wegovy has injection and tablet formulations with indication-specific dosing. See the formulation and dosing sections above; matching the active ingredient does not make these products or their doses interchangeable.

Which is better: semaglutide or tirzepatide?

The comparative evidence discussed here concerns the specific products studied; the cited trials do not establish outcomes for compounded versions. Both tirzepatide and semaglutide are GLP-1-based medications. Individual results vary significantly. Read our detailed comparison.

Can I take semaglutide if I don’t have diabetes?

Yes. The FDA-approved Wegovy product is indicated for weight loss in people without diabetes who have a BMI ≥30 or BMI ≥27 with weight-related health conditions. You don’t need diabetes to be a candidate for semaglutide for weight management.

Will semaglutide cause muscle loss?

A change on the scale alone does not tell you how much muscle you have lost. Discuss strength, function and nutrition with your clinician or dietitian, particularly if eating becomes difficult or you feel weaker. This article does not establish a universal protein target or exercise prescription for every person taking semaglutide.

Can I get pregnant while taking semaglutide?

Pregnancy can occur during treatment; semaglutide is not contraception. For Wegovy used for weight reduction or cardiovascular risk reduction, follow the stop and pregnancy-planning instructions in the safety section above. Discuss pregnancy prevention or plans and the exact product’s guidance with your prescriber. Other indications require their own assessment.

Is there a pill form of semaglutide?

Yes. The labels linked above cover Rybelsus, Ozempic tablets and Wegovy tablets. Their indications, strengths and escalation instructions differ. Ask your prescriber which exact product is appropriate; a tablet is not a milligram-for-milligram substitute for an injection. See our oral vs injectable comparison.

Conclusion: Is Semaglutide Right for You?

FDA-approved semaglutide medications (Wegovy, Ozempic) demonstrated significant results in clinical trials. Important: Compounded semaglutide is NOT FDA-approved. The FDA does not verify the safety or effectiveness of compounded medications, and the cited trials do not establish outcomes for compounded semaglutide. The clinical figures throughout this article are from trials of FDA-approved products and should not be assumed to apply to compounded semaglutide. Individual results vary significantly based on adherence, diet, and exercise.

Semaglutide may be worth discussing with your clinician if you:

• Have struggled to lose weight or maintain weight loss with diet and exercise alone
• Have a BMI ≥30 or BMI ≥27 with weight-related health conditions
• Are open to a treatment plan whose duration your clinician sets and revisits with you
• Can combine medication with lifestyle improvements
• Don’t have contraindications like a personal or family history of medullary thyroid cancer (MTC) or MEN 2

Ready to get started?

Our program connects you with a licensed provider who evaluates whether treatment is appropriate for you and directs your dosing. If a compounded medication is prescribed, it is prepared individually for you by a state-licensed 503A compounding pharmacy based on your prescription. Compounded semaglutide is NOT FDA-approved.

• Initial medical consultation with a licensed provider
• Clinician-directed prescription and dosing plan
• Medication prepared individually for you by a state-licensed 503A compounding pharmacy (if prescribed)
• Injection supplies and detailed instructions
• Ongoing medical support and clinician-directed dose adjustments
• No hidden fees and no long-term contracts. Plans are billed monthly on a recurring basis until you cancel. You can stop future renewals before your next billing date by emailing info@joinboca.com; once a provider has completed your review and written a prescription, cancellation requires written notice within 24 hours and a $50 professional fee applies. See Boca’s Refund Policy for full terms.

For pricing, please see current pricing on our product page. For those preferring oral medication, our oral semaglutide option provides a needle-free alternative.

Have questions? Talk with a licensed clinician about whether treatment may be appropriate for your weight loss goals.